48,868
edits
Difference between revisions of "Alpha-methylacyl-CoA racemase"
Jump to navigation
Jump to search
Alpha-methylacyl-CoA racemase (view source)
Revision as of 03:00, 22 September 2015
, 03:00, 22 September 2015no edit summary
| Line 1: | Line 1: | ||
[[Image:Atypical_small_acinar_proliferation_-_AMACR-CK34betaE12_-_alt_--_very_high_mag.jpg|thumb|right|AMACR positivity in [[ASAP]]. CK5/6-AMACR immunostain.]] | [[Image:Atypical_small_acinar_proliferation_-_AMACR-CK34betaE12_-_alt_--_very_high_mag.jpg|thumb|right|AMACR positivity in [[ASAP]]. CK5/6-AMACR immunostain.]] | ||
'''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | '''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | ||
==General== | |||
AMACR converts testosterone to hydrotestosterone.<ref name=pmid8626825>{{Cite journal | last1 = Cai | first1 = LQ. | last2 = Zhu | first2 = YS. | last3 = Katz | first3 = MD. | last4 = Herrera | first4 = C. | last5 = Baéz | first5 = J. | last6 = DeFillo-Ricart | first6 = M. | last7 = Shackleton | first7 = CH. | last8 = Imperato-McGinley | first8 = J. | title = 5 alpha-reductase-2 gene mutations in the Dominican Republic. | journal = J Clin Endocrinol Metab | volume = 81 | issue = 5 | pages = 1730-5 | month = May | year = 1996 | doi = 10.1210/jcem.81.5.8626825 | PMID = 8626825 }}</ref> | |||
==Positive== | ==Positive== | ||